retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Trial of for Obesity Retatrutide: A Triple Agonist Shaping

Triple receptor agonists have the potential to further bridge the efficacy gap in WL between BS and the currently approved obesity pharmacotherapies, with the added potential for other synergistic metabolic benefits, such as improving glycaemia in people with T2D, and treating or preventing MASLD/MASH

Dont rely on online BAC calculators or standard waiting periods

J Clin Endocrinol Metab (2016) 101(5):193544.10.1210/jc.2015-2583 167 JansenPLvan WervenJAartsEBerendsFJanssenIStokerJet alAlterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery

It is unclear what would happen to peoples habits after they stop using the drugs, or whether there would be a lasting impact on users health and consumption patterns

They are also contraindicated in those with personal or family history of medullary thyroid carcinoma and those with multiple endocrine neoplasia type 2

This report is based on the 43 that could be analyzed